ES2962812T3 - Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos - Google Patents

Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos Download PDF

Info

Publication number
ES2962812T3
ES2962812T3 ES19878837T ES19878837T ES2962812T3 ES 2962812 T3 ES2962812 T3 ES 2962812T3 ES 19878837 T ES19878837 T ES 19878837T ES 19878837 T ES19878837 T ES 19878837T ES 2962812 T3 ES2962812 T3 ES 2962812T3
Authority
ES
Spain
Prior art keywords
aoah
msc
polypeptide
promoter
mscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19878837T
Other languages
English (en)
Spanish (es)
Inventor
Michael Callahan
Shirley H J Mei
Yan Wang
Maria Florian
Katelynn Rowe
Chyan-Jang Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ottawa Hospital
United Therapeutics Corp
Original Assignee
Ottawa Hospital
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital, United Therapeutics Corp filed Critical Ottawa Hospital
Application granted granted Critical
Publication of ES2962812T3 publication Critical patent/ES2962812T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES19878837T 2018-10-29 2019-10-29 Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos Active ES2962812T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (1)

Publication Number Publication Date
ES2962812T3 true ES2962812T3 (es) 2024-03-21

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19878837T Active ES2962812T3 (es) 2018-10-29 2019-10-29 Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos

Country Status (10)

Country Link
US (1) US20220010281A1 (cg-RX-API-DMAC7.html)
EP (1) EP3874029B1 (cg-RX-API-DMAC7.html)
JP (1) JP7372982B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210086662A (cg-RX-API-DMAC7.html)
CN (1) CN113166729A (cg-RX-API-DMAC7.html)
AU (1) AU2019370629A1 (cg-RX-API-DMAC7.html)
ES (1) ES2962812T3 (cg-RX-API-DMAC7.html)
IL (1) IL282820A (cg-RX-API-DMAC7.html)
SG (1) SG11202103509RA (cg-RX-API-DMAC7.html)
WO (1) WO2020087160A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302060A (en) * 2020-10-16 2023-06-01 Ottawa Hospital Res Inst Cell-based therapy for viral diseases
CN116570711A (zh) * 2022-12-21 2023-08-11 上海交通大学医学院附属第九人民医院 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用
WO2026101889A2 (en) * 2024-11-06 2026-05-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Acyloxyacyl hydrolase and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
JP2011528566A (ja) * 2008-07-21 2011-11-24 コンプジェン リミティッド アンジオポエチン由来ペプチド
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
JP2012529895A (ja) * 2009-06-19 2012-11-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗egfr抗体の癌療法における有効性を決定するためのバイオマーカーおよび方法
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
RU2658490C2 (ru) * 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
CA2928852A1 (en) * 2013-11-01 2015-05-07 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
KR102213527B1 (ko) * 2014-06-30 2021-02-09 타이제닉스, 에스.에이.유. 패혈증 치료용 중간엽 기질세포
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
CA3172801A1 (en) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
CN108430480B (zh) * 2015-09-15 2022-08-02 康干细胞生物科技有限公司 一种包含过表达sod3的干细胞作为活性成分的炎症性疾病的预防或治疗用组合物

Also Published As

Publication number Publication date
AU2019370629A1 (en) 2021-05-20
WO2020087160A1 (en) 2020-05-07
EP3874029A1 (en) 2021-09-08
EP3874029B1 (en) 2023-08-30
KR20210086662A (ko) 2021-07-08
CN113166729A (zh) 2021-07-23
US20220010281A1 (en) 2022-01-13
IL282820A (en) 2021-06-30
EP3874029A4 (en) 2022-08-03
JP2022513379A (ja) 2022-02-07
JP7372982B2 (ja) 2023-11-01
CA3116196A1 (en) 2020-05-07
SG11202103509RA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
KR101992807B1 (ko) 조직 재생을 유도하기 위한 펩티드 및 그의 이용
ES2629086T3 (es) Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
Mei et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1
ES2739129T3 (es) IL-22 para uso en el tratamiento de la enfermedad gastrointestinal del injerto contra el huesped
CN102711777B (zh) 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
US20110097309A1 (en) Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue
ES3032739T3 (en) Genetically engineered hematopoietic stem cell as a platform for systemic protein expression
ES2927406T3 (es) Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil
ES2727820T3 (es) Células madre mesenquimatosas modificadas genéticamente que expresan alfa-1 antitripsina (AAT)
US20190117702A1 (en) Use of asc and asc-cm to treat ards, sars, and mers
ES2581278T3 (es) Composiciones y métodos para la inmunomodulación
EP3874029B1 (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
JP5706821B2 (ja) ペリオスチンに誘導される膵臓再生
JP7672636B2 (ja) 間葉系幹細胞の動員活性を有するペプチド
Naso et al. Cellular therapy options for genetic skin disorders with a focus on recessive dystrophic epidermolysis bullosa
JP2024522256A (ja) 免疫寛容を誘導するための合成タンパク質
CA3116196C (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
HK40057211A (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
HK40057211B (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
US20230414668A1 (en) Cell-based therapy for viral diseases
Venkatakrishnan Cell and Gene Therapy for Treating Acquired and Inherited Corneal Disorders
Khalili A novel cell therapy for xerostomia in Non-Obese Diabetic mice
Provost The role of interferon gamma in the regulation of the epithelial responses in allergic airway inflammation
Thawer The role of pulmonary innate and adaptive immune responses to helminth infection